# US 2022/0031703 A9 · Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031703 A9
- Document ID: US20220031703A9
- Status: Published application
- Kind: A9
- Application number: 17/153,749
- Filed: 2021-01-20
- Published: 2022-02-03
- Earliest claimed: 2014-03-31
- Assignees: Vasopharm GmbH
- Applicants: Vasopharm GmbH
- Inventors: Peter SCHEURER; Frank TEGTMEIER; Reinhard SCHINZEL
- Web page: https://patentgrep.com/patent/US20220031703A9

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 47/02: Inorganic compounds
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for preparing a lyophilized solid pharmaceutical composition comprising a) a compound having the formula (I): and/or a compound having the formula (II): and b) two different sodium phosphate salts, wherein the two different sodium phosphate salts are NaH2PO4.2H2O and Na2HPO4.2H2O, and wherein the quantity of the NaH2PO4.2H2O and Na2HPO4.2H2O present in the composition is chosen such that the molar ratio of both NaH2PO4.2H2O and Na2HPO4.2H2O to compound (I) or compound (II) ranges from 0.02 to 0.5.

## Claims

### Claim 1

A method for preparing a lyophilized solid pharmaceutical composition comprising
a) a compound having the formula (I):
and/or a compound having the formula (II):
and
b) two different sodium phosphate salts, wherein the two different sodium phosphate salts are NaH2PO4.2H2O and Na2HPO4.2H2O, and wherein the quantity of the NaH2PO4.2H2O and Na2HPO4.2H2O present in the composition is chosen such that the molar ratio of both NaH2PO4.2H2O and Na2HPO4.2H2O to compound (I) or compound (II) ranges from 0.02 to 0.5 and optionally NaCl;
the method comprising:
aa) dissolving the compound of the formula (III) and/or (II):
with a buffer, wherein the buffer comprises the two different sodium phosphate salts, wherein the buffer is prepared by
separately dissolving in water NaH2PO4.2H2O and Na2HPO4.2H2O,
then adding the NaH2PO4.2H2O solution to the Na2HPO4.2H2O solution to obtain a sodium phosphate solution with a pH of 7.4.
adding the sodium phosphate solution to a 5N NaOH solution;
bb) lyophilization of the solution obtained in aa).

### Claim 2 (depends on 1)

The method of claim 1, wherein the lyophilisate obtained in bb) is filled into a 50 ml vial.

### Claim 3 (depends on 2)

The method of claim 2, wherein the lyophilisate obtained in bb) is filled into a 50 ml vial (i) in an amount of about 1-1.5 g; or
(ii) in an amount of about 0.9-1.4 g.

### Claim 4 (depends on 3)

The method of claim 3, wherein the buffer comprises 12-16% (w/w) NaOH 5N, 8-12% (w/w) sodium hydrogen phosphate buffer and 74-78% (w/w) water for injection.

### Claim 5 (depends on 4)

The method of claim 4, wherein the buffer comprises 12-16% (w/w) NaOH 5N, 8-12% (w/w) sodium hydrogen phosphate buffer and 74-78% (w/w) water for injection.

### Claim 6 (depends on 1)

The method of claim 1, wherein the solution obtained in aa) is sterile filtered, preferably with a 0.22 μm filter.

### Claim 7 (depends on 1)

The method of claim 1, wherein buffer is prepared with degassed buffer.

### Claim 8 (depends on 7)

The method of claim 7, wherein buffer is degassed with nitrogen until the oxygen content is <1.0 ppm.

### Claim 9 (depends on 1)

The method of claim 1, wherein after the preparation of the solution, the lyophilisation is started at most 2 hours later.

### Claim 10 (depends on 3)

The method of claim 3, wherein the lyophilisate obtained in bb) is filled into a 50 ml vial for (i) in an amount of about 1.25 g solid formulation or for (ii) in an amount of 1.15 g solid formulation.
